Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) announces pricing of underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $45.0 million.

Financial Analyst

From a financial perspective, Syros Pharmaceuticals' decision to price an underwritten offering of shares and pre-funded warrants is a strategic move to raise capital. The capital raised, approximately $45.0 million before fees, is significant for the company's operations and future research endeavors. This influx of funds can be allocated towards advancing their clinical trials, expanding their product pipeline, or scaling up manufacturing capabilities.

The offering price of $4.42 per share and $4.419 per pre-funded warrant suggests a calculated approach to attract investors while aiming to minimize dilution of existing shares. Investors should consider the potential for short-term dilution against the long-term benefits of the capital increase. The company's decision to offer pre-funded warrants provides an alternative for investors who may prefer this instrument over common stock, potentially widening the investor base.

It is crucial to monitor how the market reacts to this offering. A positive reception could indicate investor confidence in Syros' growth potential, whereas a negative response might reflect concerns over the company's current valuation or its ability to generate returns on the new capital.

Biotech Industry Analyst

The biopharmaceutical sector is highly competitive and capital-intensive, particularly in the area of hematologic malignancies. Syros Pharmaceuticals' move to secure additional funding is indicative of the substantial costs associated with bringing new treatments through the clinical and regulatory pipelines. The successful closing of this offering will be crucial for maintaining momentum in their research and development efforts.

Investors should assess the impact of this financial initiative in the context of Syros' pipeline robustness, stage of clinical trials and the company's historical burn rate. The ability to raise funds is often a proxy for the market's belief in a company's potential to bring viable treatments to market. However, it is also essential to scrutinize the company's track record in managing capital and advancing its clinical programs.

While the gross proceeds of $45.0 million are substantial, they must be weighed against the ongoing and future costs of clinical trials, which can run into hundreds of millions. The efficiency with which Syros utilizes the raised capital will be a critical factor in its ability to deliver shareholder value.

Healthcare Investment Advisor

Investors in the healthcare sector are typically driven by the potential for significant returns, which are often realized upon successful product development, regulatory approvals and commercialization. For Syros Pharmaceuticals, the capital raise through an underwritten offering is a pivotal event that can provide the necessary resources to reach these milestones.

However, the investment risk is inherent in this sector due to the unpredictable nature of clinical trial outcomes. The price per share and warrant in this offering reflects current market conditions and investor sentiment towards the company's prospects. It is advisable for investors to consider the balance between the immediate dilutive effect of the new shares and warrants and the potential long-term value creation derived from their intended use.

Additionally, the structure of the offering, including the provision of pre-funded warrants, may appeal to a broader range of investors, including those looking for a different risk-reward profile compared to traditional stock offerings. This could be a strategic move by Syros to diversify its investor base and enhance financial flexibility.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 per pre-funded warrant, which would result in total gross proceeds of approximately $45.0 million, before underwriting discounts and commissions and offering expenses payable by Syros. All shares and pre-funded warrants are being offered by Syros. Closing of the offering is expected to occur on or about December 21, 2023, subject to customary closing conditions.

The financing included new and existing investors, including Bain Capital Life Sciences, Syros co-founder and founding investor Flagship Pioneering, Adage Capital Partners LP, Invus, Samsara BioCapital, Deep Track Capital, Blue Owl Healthcare Opportunities, DAFNA Capital Management LLC, as well as a life sciences-focused investment fund.

TD Cowen and Piper Sandler & Co. are acting as joint book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on April 6, 2023 and declared effective by the SEC on April 28, 2023. The offering will be made only by means of the prospectus and prospectus supplement that form a part of the registration statement.

The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926, or by email at Prospectus_ECM@cowen.com or from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at 800-747-3924, or by email: prospectus@psc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the consummation of the offering as well as the gross proceeds from the offering and the anticipated uses of such proceeds. The words, without limitation, ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Syros will be able to complete the offering on the anticipated terms, or at all. Additional risks and uncertainties relating to the offering, Syros and its business can be found under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231218719088/en/

Syros Contact:

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What did Syros Pharmaceuticals announce today?

Syros Pharmaceuticals announced the pricing of an underwritten offering of 4,939,591 shares of common stock and pre-funded warrants to purchase 5,242,588 shares of its common stock.

How many shares of common stock were offered in the underwritten offering?

4,939,591 shares of common stock were offered.

What is the offering price per share of common stock?

The offering price per share of common stock is $4.42.

How much gross proceeds is Syros Pharmaceuticals expecting to raise from the offering?

Syros Pharmaceuticals is expecting to raise approximately $45.0 million in total gross proceeds.

When is the closing of the offering expected to occur?

The closing of the offering is expected to occur on or before a specified date.